Epidermal Growth Factor Receptor Market

Market Overview

Epidermal growth factor binds with protein is known as epidermal growth factor receptor protein. Epidermal growth factor receptor performs key role in signalling cell pathways to control cell division and survival. Mutations in epidermal growth factor receptor causes protein levels to fluctuate and impacts cell signalling. Reduced cell signalling leads to diseases like Alzheimer whereas over-expression causes cancer cells to divide more rapidly.

Epidermal growth factor receptor market includes drugs that inhibits protein levels used in treatment of various types of cancers. According to the American Cancer Society (ACS), around 38.4% people are diagnosed with cancer at some point of life in the U.S.

There has been shift of focus among biopharmaceutical companies to develop coronavirus cure due to Covid-19. Delay of manufacturing activities and supply chain disruption will have short term negative impact on epidermal growth factor receptor market growth rate. Reduction in diagnosis and treatment adoption rate owing to decreased patient visits to healthcare facilities is expected to delay growth of epidermal growth factor receptor market.

Increasing prevalence of various types of cancer is expected to drive the growth of epidermal growth factor receptor market. Increasing collaborative research and development activities among leading biopharmaceutical innovative players is expected to fuel the growth of epidermal growth factor receptor market. In addition, clinical-stage development companies are allocating significant funds towards the development of the epidermal growth factor receptor market.

For instance, in August 2020, the Daiichi Sankyo Company Limited and AstraZeneca announced clinical trial collaboration to evaluate an epidermal growth factor receptor tyrosine kinase inhibitor among patients with advanced EGFR mutation and metastatic non-small cell lung cancer.

Stringent regulatory procedure for drug approval is expected to hinder growth of epidermal growth factor receptor market. Lower diagnosis rate is challenging factor for epidermal growth factor receptor market growth.

Key Players

Some key players contributing in epidermal growth factor receptor market are Pfizer, Inc., Novartis AG, Hoffmann-La Roche Ltd, Amgen Inc., AstraZeneca plc., Eli Lilly and Company, Eisai, Inc., Bristol-Myers Squibb Company, Merck & Co., Johnson & Johnson, Biocon Ltd., Takeda Pharmaceutical Company, Daiichi Sankyo Company and others.

The report on Epidermal Growth Factor Receptor Market covers exhaustive analysis on:

• Market Segments
• Market Dynamics
• Historical Actual Market Size, 2015 - 2019
• Market Size & Forecast 2020 to 2030
• Supply & Demand Value Chain
• Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain
• Market Drivers and Restraints

Regional analysis for Epidermal Growth Factor Receptor Market includes

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

 Report on Epidermal Growth Factor Receptor Market Highlights:

• Shifting industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size
• Recent industry trends
• Key competition landscape
• Strategies of key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance